rizatriptan and Recrudescence studies

Research Excerpts

Excerpt	Relevance	Reference
" Although previous studies have independently compared the efficacy of these agents, contemporaneous data examining both pharmacokinetic (PK) properties and efficacy in parallel have not previously been available."	2.79	Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. ( Egan, CG; Mogavero, S; Savi, L, 2014)
"Rizatriptan 5 mg was well tolerated in both the studies, with an adverse event profile not significantly different from that of placebo or standard care."	2.71	Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. ( Cady, R; Klipfel, M; Lewis, D; McCarroll, K; Nett, R; Peng, Y; Strohmaier, K; Visser, WH; Winner, P, 2004)
"Rizatriptan has a favorable side effect profile, and, provided contraindications are observed, severe adverse cardiovascular complications are extremely unlikely."	2.70	Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes. ( Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V, 2001)
"Rizatriptan is an effective and fast acting drug for the acute treatment of migraine."	2.70	Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. ( Barbosa, JS; Krymchantowski, AV, 2002)
"Rizatriptan is a novel 5-HT1B/1D agonist which is rapidly absorbed after oral administration."	2.69	Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. ( Block, G; Cutler, N; Gross, M; Jiang, K; Reines, S; Smith, B; Teall, J; Tuchman, M; Willoughby, E, 1998)
"Rizatriptan was more effective than naratriptan."	2.69	Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. ( Allen, C; Bomhof, M; Legg, N; Patel, K; Paz, J; Vandormael, K, 1999)
"Rizatriptan 10 mg was generally superior to sumatriptan on a measure of time-to-pain-relief within 2 h, where pain relief was defined as a reduction of pain to mild or none (odds ratio for rizatriptan versus sumatriptan 100 mg = 1."	2.41	Rizatriptan: pharmacological differences from sumatriptan and clinical results. ( Lines, CR; McCarroll, KA; Visser, WH, 2001)
"Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies."	2.41	Newer intranasal migraine medications. ( Logemann, CD; Rankin, LM, 2000)
"Rizatriptan is a new, selective 5-HT1B/1D receptor agonist that is effective for treatment of migraine."	2.41	The use of rizatriptan in the treatment of acute, multiple migraine attacks. ( Saper, JR, 2000)
"Eletriptan 40 mg also was found to have the lowest total triptan cost to successfully treat 100 patients."	1.33	Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. ( Healey, PJ; Mullins, CD; Perfetto, EM; Subedi, PR; Weis, KA, 2005)

Research

Studies (14)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

No Disability at 2 Hours After the Initial Dose of Test Drug

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (21.43)	18.2507
2000's	10 (71.43)	29.6817
2010's	1 (7.14)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Savi, L	1
Mogavero, S	1
Egan, CG	1
Lines, CR	1
McCarroll, KA	1
Visser, WH	2
Winner, P	1
Strohmaier, K	1
Klipfel, M	1
Peng, Y	1
McCarroll, K	1
Cady, R	1
Lewis, D	1
Nett, R	1
Mullins, CD	1
Weis, KA	1
Perfetto, EM	1
Subedi, PR	1
Healey, PJ	1
Teall, J	1
Tuchman, M	1
Cutler, N	1
Gross, M	1
Willoughby, E	1
Smith, B	1
Jiang, K	1
Reines, S	1
Block, G	1
Deleu, D	1
Hanssens, Y	1
Bomhof, M	1
Paz, J	1
Legg, N	1
Allen, C	2
Vandormael, K	1
Patel, K	2
Logemann, CD	1
Rankin, LM	1
Pascual, J	1
Vega, P	1
Diener, HC	1
Vrijens, F	1
Saper, JR	1
Potrebic, S	1
Raskin, NH	1
Göbel, H	1
Heinze, A	1
Heinze-Kuhn, K	1
Lindner, V	1
Ferrari, MD	1
Roon, KI	1
Lipton, RB	1
Goadsby, PJ	1
Krymchantowski, AV	1
Barbosa, JS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence[NCT00897949]	Phase 3	1,473 participants (Actual)	Interventional	1995-03-31	Completed
Effects of Myofascial Trigger Points Therapy in Migraine.[NCT05646160]		100 participants (Anticipated)	Interventional	2018-01-15	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 - Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Pain Free at 2 Hours After the Initial Dose of Test Drug

Intervention	Participants (Number)
	Normal	Mildly Impaired	Severely Impaired	Requires Bedrest
Placebo	54	118	53	75
Rizatriptan 10 mg	209	148	45	52
Rizatriptan 5 mg	175	160	56	66

Patients reporting pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Pain Relief 2 Hours After Treatment for Headache Recurrence

Intervention	Participants (Number)
	Reporting no pain	Reporting pain
Placebo	30	272
Rizatriptan 10 mg	193	262
Rizatriptan 5 mg	150	307

Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours). (NCT00897949)
Timeframe: 2 hours after treatment for recurrence

Pain Relief at 2 Hours After the Initial Dose of Test Drug

Intervention	Participants (Number)
	Pain relief	No pain relief
Placebo / Rizatriptan 10 mg	18	4
Placebo / Rizatriptan 5 mg	12	5
Rizatriptan 10 mg / Placebo	33	42
Rizatriptan 10 mg / Rizatriptan 10 mg	53	12
Rizatriptan 5 mg / Placebo	32	27
Rizatriptan 5 mg / Rizatriptan 5 mg	39	16

Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Intervention	Participants (Number)
	Reporting pain relief	Not reporting pain relief
Placebo	106	196
Rizatriptan 10 mg	322	133
Rizatriptan 5 mg	285	172

Intervention	Participants (Number)
	Used escape medication	Did not use escape medication
Placebo	128	176
Rizatriptan 10 mg	76	380
Rizatriptan 5 mg	101	357

Article	Year
Rizatriptan: pharmacological differences from sumatriptan and clinical results. Current medical research and opinion, 2001, Volume: 17 Suppl 1 Topics: Administration, Oral; Humans; Migraine Disorders; Patient Satisfaction; Recurrence; Serotonin Recept	2001
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Acta neurologica Belgica, 1999, Volume: 99, Issue:2 Topics: Acute Disease; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Vasospasm; Drug Des	1999
Newer intranasal migraine medications. American family physician, 2000, Jan-01, Volume: 61, Issue:1 Topics: Administration, Intranasal; Administration, Oral; Analgesics, Non-Narcotic; Clinical Trials as Topic	2000
The use of rizatriptan in the treatment of acute, multiple migraine attacks. Neurology, 2000, Volume: 55, Issue:9 Suppl 2 Topics: Acute Disease; Humans; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; Triazoles; Trypt	2000
New abortive agents for the treatment of migraine. Advances in internal medicine, 2001, Volume: 46 Topics: Clinical Trials as Topic; Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperid	2001
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (London, England), 2001, Nov-17, Volume: 358, Issue:9294 Topics: Acute Disease; Administration, Oral; Humans; Indoles; Migraine Disorders; Pyrrolidines; Randomized C	2001

Article	Year
Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. Drug design, development and therapy, 2014, Volume: 8 Topics: Adult; Carbazoles; Cross-Over Studies; Double-Blind Method; Female; Half-Life; Humans; Male; Middle	2014
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache, 2004, Volume: 44, Issue:9 Topics: Acute Disease; Adolescent; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Recurrence	2004
Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache, 1998, Volume: 38, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migr	1998
Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. European neurology, 1999, Volume: 42, Issue:3 Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Male; Middle	1999
Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia : an international journal of headache, 2000, Volume: 20, Issue:5 Topics: Adult; Disability Evaluation; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Oxazoli	2000
Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes. Headache, 2001, Volume: 41, Issue:3 Topics: Adult; Female; Humans; Male; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; Time Facto	2001
Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia : an international journal of headache, 2002, Volume: 22, Issue:4 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Therapy,	2002

rizatriptan and Recrudescence